Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 3
2011 2
2019 1
2020 3
2021 3
2022 4
2023 1
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for M. minashi
Your search for M. Minbashi retrieved no results
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Takeuchi H, Nakamura K, Kitagawa Y; JCOG1109 investigators. Kato K, et al. Lancet. 2024 Jul 6;404(10447):55-66. doi: 10.1016/S0140-6736(24)00745-1. Epub 2024 Jun 11. Lancet. 2024. PMID: 38876133 Clinical Trial.
Patients were randomly assigned (1:1:1) centrally via a web-based system to receive neoadjuvant doublet chemotherapy (two courses of fluorouracil [800 mg/m(2) per day intravenously on days 1-5] and cisplatin [80 mg/m(2) per day on day 1] separated by an interval of …
Patients were randomly assigned (1:1:1) centrally via a web-based system to receive neoadjuvant doublet chemotherapy (two courses of fluorou …
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Doki Y, et al. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. N Engl J Med. 2022. PMID: 35108470 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study).
Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S, Sakanaka K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Takeuchi H, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):454-462. doi: 10.1016/j.ijrobp.2022.07.007. Epub 2022 Aug 4. Int J Radiat Oncol Biol Phys. 2022. PMID: 35932949
METHODS AND MATERIALS: Patients with clinical stage II/III EC (International Union Against Cancer sixth edition, non-T4) were eligible. Chemotherapy comprised cisplatin (75 mg/m(2) on days 1 and 29) and 5-fluorouracil (1000 mg/m(2)/d on days 1-4 and 29-32). Radiatio …
METHODS AND MATERIALS: Patients with clinical stage II/III EC (International Union Against Cancer sixth edition, non-T4) were eligible. Chem …
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.
Morizane C, Ueno M, Ioka T, Tajika M, Ikeda M, Yamaguchi K, Hara H, Yabusaki H, Miyamoto A, Iwasa S, Muto M, Takashima T, Minashi K, Komatsu Y, Nishina T, Nakajima TE, Takeno A, Moriwaki T, Furukawa M, Sahara T, Ikezawa H, Nomoto M, Takashima S, Uehara T, Funasaka S, Yashiro M, Furuse J. Morizane C, et al. Cancer Sci. 2025 Jan;116(1):192-203. doi: 10.1111/cas.16354. Epub 2024 Oct 27. Cancer Sci. 2025. PMID: 39462221 Free PMC article. Clinical Trial.
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Boku N, et al. Gastric Cancer. 2021 Jul;24(4):946-958. doi: 10.1007/s10120-021-01173-w. Epub 2021 Mar 20. Gastric Cancer. 2021. PMID: 33743112 Free PMC article. Clinical Trial.
An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.
Mizukami T, Minashi K, Hara H, Nishina T, Amanuma Y, Takahashi N, Nakasya A, Takahashi M, Nakajima TE. Mizukami T, et al. Invest New Drugs. 2022 Jun;40(3):614-621. doi: 10.1007/s10637-022-01223-9. Epub 2022 Mar 12. Invest New Drugs. 2022. PMID: 35278170 Clinical Trial.
METHODS: Patients who were refractory to fluoropyrimidine, platinum and taxane were enrolled into four cohorts (Level 1A/1B/2A/2B) and treated with irinotecan (100 [Level 1] or 125 [Level 2] mg/m(2) on days 1 and 15) and FTD/TPI (35 mg/m(2)/dose, twice daily, on day …
METHODS: Patients who were refractory to fluoropyrimidine, platinum and taxane were enrolled into four cohorts (Level 1A/1B/2A/2B) and treat …
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, Esaki T, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, Yoshino T, Maehara Y, Oki E. Ando K, et al. Br J Cancer. 2023 Oct;129(6):1032-1039. doi: 10.1038/s41416-023-02378-9. Epub 2023 Aug 2. Br J Cancer. 2023. PMID: 37532830 Free PMC article.
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
Tahara M, Araki K, Okano S, Kiyota N, Fuse N, Minashi K, Yoshino T, Doi T, Zenda S, Kawashima M, Ogino T, Hayashi R, Minami H, Ohtsu A. Tahara M, et al. Ann Oncol. 2011 Jan;22(1):175-180. doi: 10.1093/annonc/mdq298. Epub 2010 Jun 7. Ann Oncol. 2011. PMID: 20530200 Free article. Clinical Trial.
PATIENTS AND METHODS: treatment consisted of docetaxel (Taxotere) at doses of 50, 60, and 70 mg/m(2); cisplatin at 70 mg.m(2)/day on day 1; and S-1 twice daily on days 1-14 at doses of 40, 60, and 80 mg.m(2)/day, repeated every 3 or 4 weeks. ...Of 12 patients …
PATIENTS AND METHODS: treatment consisted of docetaxel (Taxotere) at doses of 50, 60, and 70 mg/m(2); cisplatin at 70 mg.m(2)/ …
16 results